Germany-based VSY Biotechnology, which traditionally focuses on ophthalmology and orthopaedics, has developed a new drug, called TR-C1, for Covid-19.
In laboratory conditions TR-C1 has been shown to neutralise the SARS-CoV-2 virus, which causes Covid-19, and now the drug is progressing to human clinical trials. VSY hopes to publish interim results of the first stage in the next few weeks.
VSY chairman of the board of directors Dr. Ercan Varlibas commented: "At VSY Biotechnology, we have completed many pioneering R&D projects by producing new technologies thanks to our R&D team and innovation power. Our TR-C 19 project is one of the most meaningful projects that we have been developing.”